The predominant analytical approach for quantitative pharmacokinetic and drug metabolism studies is to utilize HPLC in combination with mass spectrometry. However, the growing number of samples that are being analyzed in today's drug discovery and development labs are pushing the limits of current LC/MS system performance and throughput.

In response to these increasing demands, MS vendors continue to refine their systems for faster and more sensitive detection and quantitation. In contrast, a general-purpose HPLC system with inadequate flow control and response time for such fast separations is used for many LC/MS/MS bioanalyses. As a result, only a fraction of the potential analytical throughput is being realized.

With the release of the new ExpressHT-Ultra, Eksigent meets this challenge by delivering a short-cycle time, high-throughput HPLC system specifically designed to maximize the performance of today's mass spectrometer.

The ExpressHT-Ultra's maximum pressure of 10,000 psi enables the use of small particle size stationary phases that deliver narrow peaks to mass spectrometers. Plus, the ExpressHT-Ultra incorporates Eksigent's proprietary Microfluidic Flow Control to ensure excellent flow rate precision for small molecule analyses. The use of small internal diameter columns, combined with low flow rates and fast cycle times, results in up to 95% solvent savings.